SCHEMBL13051669

SCHEMBL13051669

CCOCCNc1ccc(-c2c(N)c3ccc(OCCOCC)cc3n2C2CCC2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 3/20 0.35
PRKDC P78527 2/20 0.31
PPARG P37231 1/20 0.31
FGFR1 P11362 1/20 0.31
CDK4 P11802 1/20 0.31
FGFR2 P21802 1/20 0.31
FGFR4 P22455 1/20 0.31
FGFR3 P22607 1/20 0.31
CCND1 P24385 1/20 0.31
EPHX2 P34913 1/20 0.30
HTR3A P46098 2/20 0.30
PDE3B Q13370 1/20 0.30
PDE3A Q14432 1/20 0.30
P2RY12 Q9H244 1/20 0.30
PIK3CA P42336 1/20 0.30
IGF1R P08069 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
HPGD P15428 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12996115 0.87 SMN1; SMN2 (0.34) NCF1PRKDCALDH1A1SMN1; SMN2
SCHEMBL14467697 0.85 ATM (0.33) NCF1PRKDCPIK3CAALDH1A1LMNA
SCHEMBL10097537 0.85 PIK3CA (0.36) PRKDCHTR3APIK3CAALDH1A1
SCHEMBL13052772 0.84 EPHX2 (0.40) EPHX2PIK3CAALDH1A1HPGD
SCHEMBL13052768 0.83 SMN1; SMN2 (0.36) EPHX2ALDH1A1HPGDSMN1; SMN2
SCHEMBL13199078 0.83 EGFR (0.33) FGFR4HTR3AALDH1A1LMNAHPGD
SCHEMBL13052780 0.82 EPHX2 (0.35) EPHX2HTR3AALDH1A1HPGDSMN1; SMN2
SCHEMBL10097529 0.82 ALDH1A1 (0.38) ALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL13051939 0.82 ALDH1A1 (0.34) EPHX2HTR3AALDH1A1HPGDSMN1; SMN2
SCHEMBL10097541 0.81 MEN1 (0.37) ALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C HAVCR2, EIF2AK2, MAVS NCF1 917/4885PRKDC 2987/4885PPARG 924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.